Cargando…

A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression

A 73-year-old male was initially treated with sorafenib for advanced stage HCC. However, the disease progressed 2 months after starting sorafenib. Progressive disease (PD) was confirmed by radiological examination, which revealed mediastinal and abdominal lymph node metastasis, pulmonary metastasis,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wada, Yoshiyuki, Takami, Yuko, Ryu, Tomoki, Ureshino, Hiroki, Imamura, Hajime, Sasaki, Shin, Saitsu, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184828/ https://www.ncbi.nlm.nih.gov/pubmed/32355493 http://dx.doi.org/10.1159/000506331

Ejemplares similares

Feasibility and safety of surgical microwave ablation for hepatocellular carcinoma in elderly patients: a single center analysis in Japan
por: Imamura, Hajime, et al.
Publicado: (2020)

Glomus tumor of the duodenum: a rare case report
por: Sasaki, Shin, et al.
Publicado: (2020)

The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma
por: Wada, Yoshiyuki, et al.
Publicado: (2016)

Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single center experience of 719 consecutive cases
por: Takami, Yuko, et al.
Publicado: (2012)

A case of small cell neuroendocrine carcinoma of the ampulla of Vater
por: Ito, Hiroharu, et al.
Publicado: (2020)

The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Wada, Yoshiyuki, et al.
Publicado: (2017)

Impact of more detailed categorization of shrinkage or progression ratio at initial imaging response after sorafenib treatment in advanced hepatocellular carcinoma patients
por: Wada, Yoshiyuki, et al.
Publicado: (2015)

Long-Term Maintenance of Complete Response after Sorafenib Treatment for Multiple Lung Metastases from Hepatocellular Carcinoma
por: Katafuchi, Eisuke, et al.
Publicado: (2015)

A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment
por: Takami, Yuko, et al.
Publicado: (2016)

Efficacy of surgical treatment using microwave coagulo-necrotic therapy for unresectable multiple colorectal liver metastases
por: Wada, Yoshiyuki, et al.
Publicado: (2016)

Predictive Factors for Local Recurrence after Intraoperative Microwave Ablation for Colorectal Liver Metastases
por: Wada, Yoshiyuki, et al.
Publicado: (2022)

Conversion surgery for initially unresectable carcinoma of the ampulla of Vater following pathological complete response to chemotherapy: a case report
por: Sato, Yo, et al.
Publicado: (2019)

Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma
por: Kamachi, Naoki, et al.
Publicado: (2021)

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
por: Reig, Maria, et al.
Publicado: (2020)

Ramucirumab-Induced Hepatocellular Carcinoma Rupture and Gastrointestinal Perforation
por: Haider, Asim, et al.
Publicado: (2021)

Long-term survival of a patient with recurrent gallbladder carcinoma, treated with chemotherapy, immunotherapy, and surgery: a case report
por: Kawamoto, Makoto, et al.
Publicado: (2018)

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib
por: Kasuya, Kayoko, et al.
Publicado: (2020)

Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy
por: Choucair, Khalil, et al.
Publicado: (2021)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein
por: Gilabert, Marine, et al.
Publicado: (2018)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence
por: De Luca, Emmanuele, et al.
Publicado: (2020)

Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
por: Zhu, Andrew X., et al.
Publicado: (2021)

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma
por: Sugimoto, Rie, et al.
Publicado: (2022)

Gastric cancer presenting with ramucirumab-related gastrocolic fistula successfully managed by colonic stenting: a case report
por: Fukuya, Hiroki, et al.
Publicado: (2023)

Ramucirumab: preclinical research and clinical development
por: Aprile, Giuseppe, et al.
Publicado: (2014)

Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
por: Kanogawa, Naoya, et al.
Publicado: (2023)

First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation
por: Ishibashi, Naoya, et al.
Publicado: (2023)

A case of ramucirumab-induced renal failure with nephrotic-range proteinuria and its pathological findings
por: Nakano, Yuta, et al.
Publicado: (2021)

Supraduodenal and Right Gastric Arteries Originating from A Common Trunk: A Rare Anatomical Variant
por: Wada, Noriaki, et al.
Publicado: (2021)

Clinical utility of ramucirumab in advanced gastric cancer
por: Chan, Matthew MK, et al.
Publicado: (2015)

Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)
por: Nakasya, Akio, et al.
Publicado: (2022)

A case of ramucirumab-related gastrointestinal perforation in gastric cancer with small bowel metastasis
por: Urakawa, Shinya, et al.
Publicado: (2017)

Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study
por: Chau, Ian, et al.
Publicado: (2018)

Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
por: Yoshikawa, Takaki, et al.
Publicado: (2019)

Ramucirumab: A New Therapy for Advanced Gastric Cancer
por: Oholendt, Andrea Landgraf, et al.
Publicado: (2015)

Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients
por: O'Brien, Lisa, et al.
Publicado: (2017)

Gastric perforation related to concurrent use of nintedanib and ramucirumab
por: Takahashi, Saeko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sqooq6lcohi82vr9k17ccgupr6